Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study

E Gobbini, D Galetta, M Tiseo, P Graziano, A Rossi, E Bria, M Di Maio, G Rossi, V Gregorc, F Riccardi, Vieri Scotti, A Ceribelli, Lucio Buffoni, A Delmonte, T Franchina, Maria Rita Migliorino, Diego Cortinovis, S Pisconti, Paola Bordi, A CatinoE Maiello, Francesca Arizio, S Novello, on behalf of other Co-Authors

Research output: Contribution to journalArticlepeer-review


Objectives Molecular profiling of advanced non-small-cell lung cancer (NSCLC) is recommended according to European and Italian guidelines. However, molecular routine assessment remains still heterogeneous. This observational study aimed to take a picture of the real clinical practice in molecular testing and therapeutic choices in advanced Italian NSCLCs. Materials and methods This study prospectively enrolled newly diagnosed advanced or recurrent NSCLCs referred to 38 Italian centres, from November 2014 to November 2015. Information regarding molecular profiling and treatment choices were collected. Description of patients’ outcome included overall survival (OS), progression-free survival in first (PFS1) and second-line (PFS2). Results and conclusion Among 1787 patients enrolled, 1388 (78%) performed at least one molecular analysis during the history of disease: 76% were tested for EGFR, 53% for ALK, 27% for KRAS, 16% for ROS1, 14% for BRAF, 5% for HER2, 4% for MET and 1% for FGFR. The remaining 399 patients (22.3%) did not receive any molecular test. Among patients receiving at least one molecular analysis, 583 (42%) presented a molecular alteration. Considering EGFR mutated and/or ALK rearranged patients (402), for which target agents were routinely reimbursed at time of study in Italy, the 86% received a personalized treatment as first and/or second line: the 90% (286) of EGFR mutants received an EGFR tyrosine kinase inhibitor, mostly gefitinib (41.1%) or afatinib (36.4%) while 74% (62) of ALK translocated patients received an ALK inhibitor, mostly crizotinib (64%). Median OS was 9.34 months (95% CI 8.62–10.0), median PFS1 was 4.61 months (95%CI 4.31–4.84) and median PFS2 was 2.76 months (95%CI 2.57–3.19). In the Italian clinical practice, routine molecular assessment was largely applied in NSCLC patients, according to national guidelines, but a low level of ALK test was reached. Most of EGFR mutants an ALK rearranged patients received a personalized treatment as first and/or second line. © 2017 Elsevier B.V.
Original languageEnglish
Pages (from-to)30-37
Number of pages8
JournalLung Cancer
Issue number6
Publication statusPublished - 2017


Dive into the research topics of 'Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study'. Together they form a unique fingerprint.

Cite this